Acumen Pharmaceuticals Inc (ABOS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.18+2.91%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ABOS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ABOS — earnings miss
Dated 2026-08-12
of this Report (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “ Securities Act ”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Why it matters: Cash updates will show if Acumen can fund its operations and trials. This is vital for investor confidence.
Worry ifCash and equivalents are over $100 million. This shows strong funding for operations.
Less concerning ifCash and equivalents fall below $80 million. This raises worries about funding.
Why it matters: The earnings report will show how the company is doing. It will also share future plans. Investors want to know the company's direction.
Watch forAn announcement of the next earnings report date within the next month.
Also watch forThere is no news on when the next earnings report will be. This may mean delays or problems.
Why it matters: Licensing two EBD candidates could improve Acumen's pipeline. It may also help in the market. This could bring new treatments for Alzheimer's.
Supportive ifThe deal for ACU301 and ACU401 was announced with JCR Pharmaceuticals.
Worry ifNo announcement of licensing deal or delays in the EBD program.
Why it matters: Watching cash burn will help see if Acumen can keep running its clinical trials.
Worry ifCash burn rate decreases as R&D expenses continue to decline.
Less concerning ifCash burn rate goes up a lot, showing financial trouble.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$256 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $684 loss on $10,000 · 6.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,739 loss on $10,000 · 37.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: This shows progress in Acumen's Enhanced Brain Delivery program. Success could help treat Alzheimer's.
Supportive ifTwo EBD candidates were picked for more development.
Worry ifThere is no news on EBD candidates or delays in development.
Why it matters: If revenue growth in the healthcare sector picks up, it could benefit Acumen's performance. It shows a healthier market.
Supportive ifHealthcare sector revenue growth is speeding up again toward 10% or more.
Worry ifHealthcare sector revenue growth keeps slowing down below current levels.
Why it matters: Submitting the IND will show progress in developing new Alzheimer's treatments. This is key for the pipeline.
Supportive ifThe IND for the lead EBD candidate is submitted by mid-2027 as planned.
Worry ifThe IND submission is delayed beyond mid-2027.
Why it matters: Topline results will show if sabirnetug is effective for early Alzheimer's. This is a key milestone for the company.
Supportive ifALTITUDE-AD shows good results on the iADRS scale.
Worry ifTopline results show no strong effects on the iADRS scale.
Why it matters: Watching cash levels is important. They affect how a company can operate. Big changes may mean funding problems.
Worry ifThe cash balance is over $100 million. This helps support operations into early 2027.
Less concerning ifCash balance falls below $80 million, raising concerns about funding for ongoing projects.